Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TearGlyde reconditioning system is a proprietary component included in multipurpose contact lens cleaning solutions such as OPTI-FREE Replenish. It is a dual-action system containing components like Tetronic 1304 (a poloxamine surfactant) and nonanoyl ethylenediaminetriacetic acid (C9-ED3A), which adsorb to the surface and matrix of soft contact lenses (including silicone hydrogels) to maintain a thin, continuous layer of moisture on the lens throughout the day[2][3][5][6][9]. The system works synergistically with natural tear components to enhance lens wettability and wearer comfort by reducing friction and dryness[3][6]. It is not a molecular therapeutic target, receptor, or enzyme, and has no recognized role as a disease biomarker or point of interaction for pharmacological agents. TearGlyde reconditioning system is a formulation technology, not a drug target or biological entity. The entry is incorrect as a "target molecule/receptor" and should be flagged for exclusion from structured databases of molecular targets[2][3][5][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TearGlyde reconditioning system.